{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Combined+Immunodeficiency", "query": { "condition": "Severe Combined Immunodeficiency" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 73, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Combined+Immunodeficiency&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:32:22.117Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05545319", "title": "A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)", "Coronavirus Disease 2019 (COVID-19)", "Immunocompromised", "Hospitalization", "Child, Hospitalized" ], "interventions": [ { "name": "Nirmatrelvir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo for nirmatrelvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2022-12-13", "completion_date": "2024-01-06", "has_results": false, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 2, "location_summary": "Cooperstown, New York • New York, New York", "locations": [ { "city": "Cooperstown", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05545319" }, { "nct_id": "NCT04528355", "title": "Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Immunodeficiency (PID)", "Congenital Bone Marrow Failure Syndromes", "Inherited Metabolic Disorders (IMD)", "Hereditary Anemias", "Inflammatory Conditions" ], "interventions": [ { "name": "data collection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "60 Years", "sex": "ALL", "summary": "2 Months to 60 Years" }, "enrollment_count": 50, "start_date": "2020-08-20", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04528355" }, { "nct_id": "NCT00845416", "title": "Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Severe Combined Immunodeficiency", "T Cell Lymphocytopenia" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "30 Days", "sex": "ALL", "summary": "1 Day to 30 Days" }, "enrollment_count": 1800, "start_date": "2009-03", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2012-07-16", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 2, "location_summary": "Chinle, Arizona • Tuba City, Arizona", "locations": [ { "city": "Chinle", "state": "Arizona" }, { "city": "Tuba City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00845416" }, { "nct_id": "NCT00043225", "title": "The Role of Bacteria and Genetic Variations in Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psuedomas Infection", "Cystic Fibrosis" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "9 Years to 80 Years" }, "enrollment_count": 76, "start_date": "2001-06-20", "completion_date": "2018-07-10", "has_results": false, "last_update_posted_date": "2021-06-29", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 4, "location_summary": "Bethesda, Maryland • Seattle, Washington • Madison, Wisconsin + 1 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043225" }, { "nct_id": "NCT01821781", "title": "Immune Disorder HSCT Protocol", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immune Deficiency Disorders", "Severe Combined Immunodeficiency", "Chronic Granulomatous Disease", "X-linked Agammaglobulinemia", "Wiskott-Aldrich Syndrome", "Hyper-IgM", "DiGeorge Syndrome", "Chediak-Higashi Syndrome", "Common Variable Immune Deficiency", "Immune Dysregulatory Disorders", "Hemophagocytic Lymphohistiocytosis", "IPEX", "Autoimmune Lymphoproliferative Syndrome", "X-linked Lymphoproliferative Syndrome" ], "interventions": [ { "name": "Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 20, "start_date": "2013-04-29", "completion_date": "2026-04", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01821781" }, { "nct_id": "NCT01390220", "title": "Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "USL261", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 292, "start_date": "2011-06", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2019-10-10", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01390220" }, { "nct_id": "NCT01529827", "title": "Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Aplastic Anemia", "Burkitt Lymphoma", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Congenital Amegakaryocytic Thrombocytopenia", "Diamond-Blackfan Anemia", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Paroxysmal Nocturnal Hemoglobinuria", "Peripheral T-cell Lymphoma", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Secondary Myelofibrosis", "Severe Combined Immunodeficiency", "Severe Congenital Neutropenia", "Shwachman-Diamond Syndrome", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Waldenstrom Macroglobulinemia", "Wiskott-Aldrich Syndrome" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "3 Years to 75 Years" }, "enrollment_count": 94, "start_date": "2012-02-28", "completion_date": "2019-08-29", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01529827" }, { "nct_id": "NCT00001013", "title": "Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumonia, Pneumocystis Carinii", "HIV Infections" ], "interventions": [ { "name": "Trimetrexate glucuronate", "type": "DRUG" }, { "name": "Pentamidine isethionate", "type": "DRUG" }, { "name": "Sulfamethoxazole-Trimethoprim", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 364, "start_date": null, "completion_date": "1991-09", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 23, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001013" }, { "nct_id": "NCT05432310", "title": "Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenosine Deaminase Severe Combined Immune Deficiency" ], "interventions": [ { "name": "A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": null, "sex": "ALL", "summary": "1 Month and older" }, "enrollment_count": 20, "start_date": "2023-01-04", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432310" }, { "nct_id": "NCT00490100", "title": "Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Growth Failure", "X-linked Severe Combined Immunodeficiency (XSCID)", "Growth Hormone Resistence" ], "interventions": [ { "name": "Increlex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 6, "start_date": "2007-06", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-07-03", "last_synced_at": "2026-05-21T22:32:22.117Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490100" } ] }